139 related articles for article (PubMed ID: 23166385)
41. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
42. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
[TBL] [Abstract][Full Text] [Related]
43. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
44. Aggressive behavior and elevated lactate dehydrogenase at baseline confer inferior prognosis in patients with primary cutaneous lymphoma.
Liu WP; Song YQ; Zheng W; Wang XP; Ding N; Zhu J
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):534-40. PubMed ID: 23763922
[TBL] [Abstract][Full Text] [Related]
45. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.
Wilcox RA; Ristow K; Habermann TM; Inwards DJ; Micallef IN; Johnston PB; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE; Markovic SN; Porrata L
Leukemia; 2011 Sep; 25(9):1502-9. PubMed ID: 21606957
[TBL] [Abstract][Full Text] [Related]
46. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.
Riihijärvi S; Fiskvik I; Taskinen M; Vajavaara H; Tikkala M; Yri O; Karjalainen-Lindsberg ML; Delabie J; Smeland E; Holte H; Leppä S
Haematologica; 2015 Feb; 100(2):238-45. PubMed ID: 25381134
[TBL] [Abstract][Full Text] [Related]
47. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
Elstrom RL; Martin P; Ostrow K; Barrientos J; Chadburn A; Furman R; Ruan J; Shore T; Schuster M; Cerchietti L; Melnick A; Coleman M; Leonard JP
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):192-6. PubMed ID: 20511164
[TBL] [Abstract][Full Text] [Related]
48. Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
Visco C; Medeiros LJ; Jones D; Smith T; Rodriguez MA; McLaughlin P; Romaguera J; Cabanillas F; Sarris AH
Ann Oncol; 2002 Aug; 13(8):1290-9. PubMed ID: 12181254
[TBL] [Abstract][Full Text] [Related]
49. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase.
Rodriguez J; Pugh WC; Romaguera JE; Luthra R; Hagemeister FB; McLaughlin P; Rodriguez MA; Swan F; Cabanillas F
Ann Oncol; 1994 Nov; 5(9):847-9. PubMed ID: 7848887
[TBL] [Abstract][Full Text] [Related]
50. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
Moskowitz CH
Ann Oncol; 2006 May; 17 Suppl 4():iv37-9. PubMed ID: 16702184
[TBL] [Abstract][Full Text] [Related]
51. Comparative outcomes between initially unresectable and recurrent cases of advanced pancreatic cancer following palliative chemotherapy.
Xue P; Kanai M; Mori Y; Nishimura T; Uza N; Kodama Y; Kawaguchi Y; Takaori K; Matsumoto S; Uemoto S; Chiba T
Pancreas; 2014 Apr; 43(3):411-6. PubMed ID: 24622071
[TBL] [Abstract][Full Text] [Related]
52. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
53. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
Bishop MR; Dickinson M; Purtill D; Barba P; Santoro A; Hamad N; Kato K; Sureda A; Greil R; Thieblemont C; Morschhauser F; Janz M; Flinn I; Rabitsch W; Kwong YL; Kersten MJ; Minnema MC; Holte H; Chan EHL; Martinez-Lopez J; Müller AMS; Maziarz RT; McGuirk JP; Bachy E; Le Gouill S; Dreyling M; Harigae H; Bond D; Andreadis C; McSweeney P; Kharfan-Dabaja M; Newsome S; Degtyarev E; Awasthi R; Del Corral C; Andreola G; Masood A; Schuster SJ; Jäger U; Borchmann P; Westin JR
N Engl J Med; 2022 Feb; 386(7):629-639. PubMed ID: 34904798
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
[TBL] [Abstract][Full Text] [Related]
55. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577
[TBL] [Abstract][Full Text] [Related]
56. Survival in patients with oral and maxillofacial diffuse large B-cell lymphoma.
Guevara-Canales JO; Morales-Vadillo R; Cava-Vergiú CE; Leite FP; Miranda Chaves Netto HD; Soares FA; Chaves Md
Braz Oral Res; 2013; 27(4):349-55. PubMed ID: 23752483
[TBL] [Abstract][Full Text] [Related]
57. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Abdallah AO; Atrash S; Shahid Z; Jameel M; Grazziutti M; Apewokin S; Kumar NS; Restrepo A; Waheed S; Van Rhee F; Heuck CJ; Johann D; Barlogie B; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):211-4. PubMed ID: 24373936
[TBL] [Abstract][Full Text] [Related]
58. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.
Suki S; Swan F; Tucker S; Fritsche HA; Redman JR; Rodriguez MA; McLaughlin P; Romaguera J; Hagemeister FB; Velasquez WS
Leuk Lymphoma; 1995 Jun; 18(1-2):87-92. PubMed ID: 8580834
[TBL] [Abstract][Full Text] [Related]
59. Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
Yang JC; Scordo M; Chau KW; Sauter CS; Yahalom J
Bone Marrow Transplant; 2022 Jun; 57(6):1038-1041. PubMed ID: 35430591
[No Abstract] [Full Text] [Related]
60. [Analysis of Related Factors of Survival and Prognosis in Patients With High-risk Refractory Lymphoma Treated with Auto-PBHSCT].
Jiang L; Zhu ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):784-788. PubMed ID: 29950220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
